ISABEL MOLINA: Open Payments
NPI 1588699227 · WILLIAMSVILLE, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,593 in 54 payments from 16 companies in 2025. Trend: 2023 $1,755 · 2024 $1,525 · 2025 $1,593
Food & beverage: $1,593
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $370 |
| Neurocrine BioSciences, Inc. | 5 | $222 |
| Teva Pharmaceuticals USA, Inc. | 5 | $187 |
| ABBVIE INC. | 14 | $147 |
| Vanda Pharmaceuticals Inc. | 4 | $114 |
| Lundbeck LLC | 3 | $86 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $83 |
| Tris Pharma Inc | 1 | $80 |
| Alkermes, Inc. | 3 | $73 |
| Bausch Health US, LLC | 3 | $67 |
Products named: CAPLYTA, INGREZZA, UZEDY, VRAYLAR, FANAPT, REXULTI, Onyda XR, ARISTADA.
Industry payments across NY — which companies pay providers there.
